GSK’s Nuvalent Deal Shows Big Pharma Is Paying Up for Scarce Cancer Growth
GSK’s $10.6 billion agreement to buy Nuvalent is a reminder that the pharmaceutical industry’s deal market is being driven less by cheap targets than by scarce assets that can plausibly change a company’s growth profile before the end of the decade. The British drugmaker said Tuesday
